Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Central Nervous System Metastases
NCT02886585Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2016
- Primary completion
- Jun 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in central nervous system metastases (4 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Intracranial Benefit Rate at 44 months, Overall Survival at 3 months and 1 more. Started Oct 2016; status: active, not recruiting.
02
Drugs
03
Conditions
central nervous system metastases
Beyond the preview
Go deeper on NCT02886585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02886585.